ichorbio released a research grade (RUO) version of the biosimilar Durvalumab on 18th November 2021. Full information about the product can be found here:
Durvalumab is a human monoclonal antibody that selectively binds to programmed cell death ligand-1 (PD-L1), blocking its interaction with the programmed death-1 (PD-1) receptor and with CD80, and thereby potentiating an immune response to tumour cells. Durvalumab is developed by Medimmune/AstraZeneca, and is sold under the trade name Imfinzi. Durvalumab is an FDA-approved immunotherapy for certain types of bladder and lung cancer.
Durvalumab is known as a checkpoint inhibitor drug.